Pierre Nouyrigat

Suggest Changes
Learn More
719 Background: weekly paclitaxel has been reported to shown high clinical activity, even in antracyclin resistant inflammatory breast cancer. Antracyclin chemotherapy are standard regimen for(More)
7090 Background: We previously reported the preliminary activity and tolerability of the combination of the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) and docetaxel in patients with(More)